Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
Vivos received FDA approval for an Investigational Device Exemption to start a first-in-human feasibility study of RadioGel, its Yttrium-90 injectable hydrogel for targeted tumor treatment. The study will enroll five patients with non-resectable papillary thyroid carcinoma at Mayo Clinic in Jacksonville, FL, to evaluate safety and feasibility.
Key figures
- Drug Name
- RadioGel
- Phase Of Trial
- Feasibility study
- Initial enrollment
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.